Comments
Sun Pharmaceutical Industries shares are seen rising on unit Taro Pharmaceutical Industries price hikes.
Taro has pushed through price increase in a couple of products, says Credit Suisse.
The new set of price increases will boost EBITDA by 4 per cent, Credit Suisse analysts Anubhav Agarwal and Chunky Shah say.
Sun Pharma, not sated by Ranbaxy deal, may spend up to $7 billion on M&A, according to bankers.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.